Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) will be posting its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period last year, the firm earned ($0.14) EPS. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Price Performance

Shares of YMAB traded up $0.23 during mid-day trading on Friday, reaching $14.74. 207,233 shares of the company's stock were exchanged, compared to its average volume of 330,090. The business's fifty day simple moving average is $14.03 and its 200-day simple moving average is $13.17. The stock has a market capitalization of $656.96 million, a PE ratio of -26.07 and a beta of 0.70. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90.

Insider Transactions at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the firm's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now owns 97,681 shares of the company's stock, valued at approximately $1,315,763.07. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Joris Wilms sold 5,000 shares of the business's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company's stock, valued at approximately $449,514. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 100,000 shares of company stock valued at $1,338,100 in the last quarter. 22.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on YMAB. Canaccord Genuity Group reissued a "buy" rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 13th. Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Finally, HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.